NCT04155749Active, not recruitingPhase 1
Study of Anitocabtagene-autoleucel in Participants With Relapsed Refractory Multiple Myeloma
Master Protocol for the Phase 1 Study of Cell Therapies for the Treatment of Patients With Relapsed Refractory Multiple Myeloma, Including Long-term Safety Follow-up
Source: ClinicalTrials.gov · Last updated 11 Feb 2026
Brief summary (registry, in English)
Master protocol for cell therapy, Phase 1 proof-of-concept studies in relapsed and refractory multiple myeloma and includes long-term safety follow-up.
- Status (registry)
- Active, not recruiting
- Phase (registry)
- Phase 1
- Study type
- Interventional
- Enrollment
- 40 (actual)
- First submitted
- 17 Oct 2019
- Start date
- 23 Dec 2019
- Primary completion date
- 3 Oct 2024
- Lead sponsor
- Kite, A Gilead Company
- Diseases
- Multiple myeloma
- NCT number
- NCT04155749
What you commit to
- Study type: Interventional · Phase 1
- Participants enrolled: 40
- From 23 Dec 2019 to the primary completion date, 3 Oct 2024
- 4 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Plasma Cell Leukemia or History of Plasma Cell Leukemia
- Patients with a history of severe hypersensitivity to DMSO should be excluded
- Active central nervous system disease involvement by malignancy or active CNS pathology
Lab values
- Severe uncontrolled intercurrent illness (e.g., infection) or laboratory abnormalities
Other
- Contraindication to fludarabine or cyclophosphamide
Who the study is looking for
- Relapsed and refractory Multiple Myeloma treated with at least 3 prior regimens of system therapy including Proteosome Inhibitor (PI), immunomodulatory drugs (IMiD), and anti-CD38 antibody (CD38mab); or has "triple-refractory" disease
- Documented measurable disease
- Adequate organ function
- Life expectancy \> 12 weeks, Eastern Cooperative Group Performance Status 0-1
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (4)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Beth Israel Deaconess Medical Center Coordinator of this site? Confirm its status | Boston | United States | Unknown status |
| Massachusetts General Hospital Coordinator of this site? Confirm its status | Boston | United States | Unknown status |
| Advanced Cellular Therapeutics Facility, DCAM 0800A Coordinator of this site? Confirm its status | Chicago | United States | Unknown status |
| Froedtert Hospital/Medical College of Wisconsin Coordinator of this site? Confirm its status | Milwaukee | United States | Unknown status |
Related publications
- Phase 1 Study of Anito-cel, a d-Domain BCMA CAR T Cell for Refractory or Recurrent Myeloma.N Engl J Med · 2026 · PMID 42777241
This page is information, not medical advice. Discuss any trial with your doctor.